SLC5A2 and chronic kidney disease: In order to understand this promising interaction, van der Aart-van der Beek et al. evaluated, by means of a post hoc analysis, SGLT2 inhibitors’ effects at different levels of protein intake, in three randomized controlled trials [39,40,41] in proteinuric CKD patients, with or without diabetes, receiving dapagliflozin [42].